258 related articles for article (PubMed ID: 25912466)
1. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Pilotte AP
Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
George S
Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
5. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Homet Moreno B; Garralda Cabanas E; Hitt R
Clin Transl Oncol; 2010 Jul; 12(7):468-72. PubMed ID: 20615823
[TBL] [Abstract][Full Text] [Related]
7. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
9. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Yang J; Ikezoe T; Nishioka C; Takezaki Y; Hanazaki K; Taguchi T; Yokoyama A
Int J Cancer; 2012 Feb; 130(4):959-66. PubMed ID: 21445973
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of gastrointestinal stromal tumours.
Judson I; Demetri G
Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
Schöffski P; Bukowski R; Flodgren P; Ravaud A
Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
13. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
Hopkins TG; Marples M; Stark D
Eur J Surg Oncol; 2008 Aug; 34(8):844-850. PubMed ID: 18082353
[TBL] [Abstract][Full Text] [Related]
16. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
18. Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
Brzozowska M; Wierzba W; Szafraniec-Buryło S; Czech M; Połowinczak-Przybyłek J; Potemski P; Śliwczyński A
Med Sci Monit; 2019 May; 25():3846-3853. PubMed ID: 31121600
[TBL] [Abstract][Full Text] [Related]
19. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
20. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
